Patents by Inventor Nicolas Danchin

Nicolas Danchin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220275105
    Abstract: A method for providing cardioprotection in a subject who experienced a myocardial infarction, including administering a therapeutically effective amount of a Granzyme B inhibitor. Following acute MI in mice, CD8+ T lymphocytes are quickly recruited and activated in ischemic heart tissue, and release Granzyme B, leading to cardiomyocyte apoptosis and deterioration of myocardial function. Antibody-mediated depletion of CD8+ T lymphocytes decreases Granzyme B content and apoptotic within the myocardium and inflammatory response. mAb mediated-CD8 depletion limits myocardial injury and improves heart function. These effects are recapitulated in mice with CD8+ T cell selective Granzyme B deficiency in mice. Granzyme B is produced by other cell types (e.g., NK cells). Global Granzyme B deletion (GzmB-/- mice) decreases apoptotic within the myocardium, reduces local pro-inflammatory signature and ultimately limits infarct size after MI.
    Type: Application
    Filed: July 31, 2020
    Publication date: September 1, 2022
    Applicants: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP), SORBONNE UNIVERSITÉ, UNIVERSITÉ DE PARIS
    Inventors: Hafid AIT-OUFELLA, Nicolas DANCHIN, Icia SANTOS ZAS, Tabassome SIMON
  • Patent number: 10948498
    Abstract: A cardiovascular event or disease is prevented or treated in a subject by measuring the expression level of soluble Triggering Receptors Expressed on Myeloid cells-1 (sTREM-1) level in a sample from the subject and comparing it to a reference level. Based on this comparison, subjects that are at risk of having or developing a cardiovascular event or disease are identified, and administered a suitable therapy.
    Type: Grant
    Filed: August 8, 2014
    Date of Patent: March 16, 2021
    Assignees: INOTREM, APHP (Assistance Publique-Hôpitaux de Paris), INSERM (Institut National de la Santé et de la Recherche Médicale), Université de Lorraine
    Inventors: Marc Derive, Sebastien Gibot, Hafid Ait-Oufella, Amir Boufenzer, Tabasomme Simon, Nicolas Danchin
  • Patent number: 9688767
    Abstract: The present invention relates to a method for predicting the survival time of a patient suffering from myocardial infarction or the recurrence of a myocardial infarction. The method comprises the steps of i) determining the expression level of BAFF in a sample from the patient, ii) comparing the expression level with a predetermined reference value and iii) providing a good prognosis of the survival time or a low risk of the recurrence of a myocardial infarction when the expression level is lower than the predetermined reference value and a poor prognosis of the survival time or a high risk of the recurrence of a myocardial infarction when the expression level is higher than the predetermined reference value.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: June 27, 2017
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Universite Paris Descartes, Universite Pierre et Marie Curie-UPMC, Assistance Publique-Hopitaux de Paris (APHP)
    Inventors: Ziad Mallat, Alain Tedgui, Tabassome Simon, Nicolas Danchin
  • Publication number: 20160187352
    Abstract: The present invention relates to a method for diagnosing a cardiovascular event or disease in a subject by measuring sTREM-1 level in a sample.
    Type: Application
    Filed: August 8, 2014
    Publication date: June 30, 2016
    Inventors: Marc DERIVE, Sebastien GIBOT, Hafid AIT-OUFELLA, Amir BOUFENZER, Tabasomme SIMON, Nicolas DANCHIN
  • Publication number: 20160024218
    Abstract: The present invention relates to a method for predicting the survival time of a patient suffering of myocardial infarction or the recurrence of a myocardial infarction in a patient who has suffered from a myocardial infarction comprising the steps consisting of i) determining the expression level of BAFF in a sample from said patient, ii) comparing said expression level with a predetermined reference value and iii) providing a good prognosis of the survival time or a low risk of the recurrence of a myocardial infarction when the expression level is lower than the predetermined reference value and a poor prognosis of the survival time or a high risk of the recurrence of a myocardial infarction when the expression level is higher than the predetermined reference value.
    Type: Application
    Filed: March 14, 2014
    Publication date: January 28, 2016
    Inventors: Ziad Mallat, Alain Tedgui, Tabassome Simon, Nicolas Danchin
  • Publication number: 20150104463
    Abstract: The present invention relates to in vitro methods and kits for predicting the risk of having a cardiovascular event in a subject. More particularly, the invention relates to an in vitro method for predicting the risk of a cardiovascular event in a subject, said method comprising the step of measuring the level of IL-17 in a blood sample obtained from said subject.
    Type: Application
    Filed: December 22, 2014
    Publication date: April 16, 2015
    Applicants: Institut National de la Sante et de la Recherche Medicale (INSERM), UNIVERSITE PARIS DESCARTES
    Inventors: Ziad MALLAT, Alain TEDGUI, Tabasomme SIMON, Nicolas DANCHIN
  • Publication number: 20140004540
    Abstract: The present invention relates to in vitro methods and kits for predicting the risk of having a cardiovascular event in a subject. More particularly, the invention relates to an in vitro method for predicting the risk of a cardiovascular event in a subject, said method comprising the step of measuring the level of IL-17 in a blood sample obtained from said subject.
    Type: Application
    Filed: January 13, 2012
    Publication date: January 2, 2014
    Applicant: UNIVERSITE PARIS DESCARTES
    Inventors: Ziad Mallat, Alain Tedgui, Tabassome Simon, Nicolas Danchin
  • Publication number: 20120225427
    Abstract: The invention relates to a method of identifying a subject having or at risk of having or developing a cardiovascular disease and/or a cardiovascular event, comprising determining, in a sample obtained from said subject, the presence or absence of a variant allele of nucleotide polymorphism (SNP) of the sPLA2 type IIA nucleic acid, wherein the SNP is selected from the group consisting of rs11573156 and rs2236771, wherein the presence of the minor allele (G) of SNP rs11573156 indicates an increased risk of having or being at risk of having or developing a cardiovascular disease and/or cardiovascular event, and the presence of the minor allele (C) of SNP rs2236771 indicates a decreased risk of having or being at risk of having or developing a cardiovascular disease and/or cardiovascular event.
    Type: Application
    Filed: August 20, 2010
    Publication date: September 6, 2012
    Applicant: INSERM (Institut National de la Sante et de la Recherche Medicale)
    Inventors: Ziad Mallat, Tabassome Simon, Nicolas Danchin